Fundraising Fox

Arvinas Holding Co. LLC

NASDAQ: ARVN

New Haven, US · Founded 2014 · Delaware corporation · 299 employees on LinkedIn · 8 known investors

Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology. It advances preclinical research into clinical-stage treatments for patients with limited or ineffective existing options.

BiotechHealthtech

Founders & leadership

SC
Sean CassidyExecutive
ML
Manuel LitchmanExecutive

Board

SSStephen Squinto
Stephen SquintoinBoard directorVenture Partner at OrbiMed
LRLiam Ratcliffe
Liam RatcliffeinBoard directorInvestor at Access Biotechnology
TSTim Shannon
Tim Shannonin𝕏Board directorGeneral Partner at Canaan Partners
KP
Kush ParmarBoard director
AL
Andrew LevinBoard director
JS
Jonathan SoderstromBoard director
BM
Brad MargusBoard director

Investors · 8

5AM VenturesBoston · $100K – $4M
Access BiotechnologyNew York City
Canaan PartnersStamford · $500K – $20Mvia Tim Shannon · board
Connecticut InnovationsNew Haven · $500K – $2M
Nextech InvestZurich · $648K – $3.2M
RA CapitalBoston
Solasta VenturesBoston
OrbiMedreportedNew York · $1M – $75Mvia Stephen Squinto · board

Reported raises · per SEC filings

Form D private placements

$129.1M disclosed across 3 rounds · 2015–2019

▶$32.5MraisedJul 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John G. HoustonExecutive Officer, Director
  • Sean CassidyExecutive Officer
  • Bradley MargusDirector
  • Kush ParmarDirector
  • Timothy ShannonDirector
  • Edward Kennedy, Jr.Director
  • Briggs MorrisonDirector
  • Liam RatcliffeDirector
  • Jakob LovenDirector
  • Ian TaylorExecutive Officer
Offering amount
$32.5M
Amount sold
$32.5M
First sale
Jul 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$55MraisedApr 2018 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew LevinDirector
  • Sean CassidyExecutive Officer
  • Tim ShannonDirector
  • Kush ParmarDirector
  • Jakob LovenDirector
  • Liam RatcliffeDirector
  • Stephen SquintoDirector
  • John D. HoustonExecutive Officer, Director
  • Jonathan SoderstromDirector
  • Brad MargusDirector
Offering amount
$55M
Amount sold
$55M
First sale
Mar 2018
Incorporated
Limited Liability Company, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$41.6MraisedOct 2015 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen SquintoDirector
  • Liam RatcliffeDirector
  • Andrew LevinDirector
  • Sean CassidyExecutive Officer
  • Tim ShannonDirector
  • Jonathan SoderstromDirector
  • Brad MargusDirector
  • Manuel LitchmanExecutive Officer, Director
  • Kush ParmarDirector
Offering amount
$41.6M
Amount sold
$41.6M
First sale
Oct 2015
Incorporated
Limited Liability Company, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Bioworld37 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Arvinas Holding Co. LLC for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2016$1.1M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Arvinas Holding Co. LLC - Connecticut Innovations Connecticut Innovationsctinnovations.com · Oct 2018

Frequently asked questions

What does Arvinas Holding Co. LLC do?
Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology. It advances preclinical research into clinical-stage treatments for patients with limited or ineffective existing options.
Who are Arvinas Holding Co. LLC's investors?
Arvinas Holding Co. LLC's investors include 5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Nextech Invest, RA Capital, Solasta Ventures, OrbiMed.
How much funding has Arvinas Holding Co. LLC raised?
Arvinas Holding Co. LLC has disclosed $129.1M raised across 3 rounds.
Where is Arvinas Holding Co. LLC headquartered?
Arvinas Holding Co. LLC is headquartered in New Haven, US.